Newswire (Published: Tuesday, March 28, 2017, Received: Thursday, March 23, 2017, 7:16:42 PM CDT)

Word Count: 460

By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news reporting originating from Toronto, Canada, by NewsRx editors, the research stated, "The approach of active surveillance for low-risk prostate cancer has evolved in many ways since its introduction 20 years ago. There is a great deal of ongoing research addressing the molecular genetics and clinical outcome of low-risk disease, the use of MRI and biomarkers, and the role of lifestyle and dietary modifications."

Our news editors obtained a quote from the research from the University of Toronto, "The major developments in the field are reviewed in this article. Low risk and many cases of low-intermediate risk prostate cancer are indolent, have little or no metastatic potential, and do not pose a threat to the patient in his lifetime. These are termed clinically insignificant. Studies over the last 20 years have advanced our understanding of who these patients are, and promoted the use of conservative management in such individuals. A key component of this approach is the early identification of those patients who have been misattributed as having low-risk disease, who in fact harbor higher risk disease and are likely to benefit from definitive therapy. This represents about 30% of newly diagnosed low-risk patients. A further small proportion of patients with low-risk disease demonstrate biological progression to higher grade disease. Extent of Gleason 6 on biopsy, Prostate Specific Antigen density, and race are predictors for the likelihood of coexistent higher grade cancer. The results of active surveillance, embodying conservative management with selective, delayed intervention for the subset who are reclassified as higher risk over time based on repeat biopsy, imaging, or biomarker results, have shown that this approach is safe in the intermediate to long term, with a 0.5-3% cancer-specific mortality at 10-15 years."

According to the news editors, the research concluded: "Further refinement incorporating MRI and targeted biopsies is the subject of intensive research at the moment, and promises to improve the safety and precision of conservative management."

For more information on this research see: Active surveillance for low-risk prostate cancer. Current Opinion In Urology, 2017;():. (Lippincott Williams and Wilkins - www.lww.com; Current Opinion In Urology - journals.lww.com/co-urology/pages/default.aspx)

The news editors report that additional information may be obtained by contacting L. Klotz, Division of Urology Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada (see also Oncology - Prostate Cancer).

Keywords for this news article include: Canada, Toronto, Ontario, Genetics, Oncology, Epidemiology, Prostate Cancer, Prostatic Neoplasms, North and Central America, Diagnostics and Screening.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

Lippincott Williams & Wilkins
Wolters Kluwer N.V.
Wolters Kluwer N.V.
Wolters Kluwer N.V.

Places

Central America
North America
Canada
Americas
Ontario
Toronto

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Medical Research
                  Clinical Outcomes
      Medical Specialties and Practices
            Urology